<DOC>
	<DOCNO>NCT01327859</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy donepezil ( Aricept ) Parkinson 's Disease ( PD ) patient dementia .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Donepezil ( Aricept ) Parkinson ' Disease ( PD ) Patients With Dementia</brief_title>
	<detailed_description>Patients complete 24 week double-blind study E2020-E044-316 ( NCT00165815 ) eligible open label extension study . Patients caregiver/study partner need provide additional write informed consent participate open label extension study . Safety tolerability assess 4 , 8 12 , 24 , 36 52 week . Cognition , Global Clinical Function , Activities Daily Living , Behaviour assess 24 , 52 week .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Age range : patient must age 40 Sex distribution : male female PD accord UK Brain Bank criterion 40 good response levodopa judge investigator opinion . Women child bear potential must demonstrate negative serum beta human chorionic gonadotropin ( BHCG ) screen visit doubleblind study ( E2020E044316 ) ( NCT00165815 ) negative urine test result screen visit open label extension study , ( E2020E044318 ) Completed 24 treatment week doubleblind study E2020E044316 ( NCT00165815 ) complete assessment . Outpatients , responsible reliable caregiver/study partner Health : generally healthy ambulatory ambulatoryaided ( i.e. , walker cane ) ; vision ( glass , contact lens permissible ) , hear ( hear aid permissible ) speech sufficient compliance testing procedure ; must capable swallow study medication . Written informed consent must obtain patient his/her caregiver/study partner prior subject patient caregiver/study partner open label extension study related procedure . Pregnant lactating , woman . Women childbearing potential unless : surgically sterile must practice effective contraception ( e.g . abstinence , IUD barrier method plus hormonal method ) . These patient must willing remain current form contraception duration study , ( post menopausal woman must amenorrheic least 12 month consider nonchild bear potential ) . Patients evidence psychiatric/neurological disorder , i.e. , stroke , schizophrenia , seizure disorder , head injury loss consciousness ( least 1 hour ) within past year , progressive supranuclear palsy , multisystem atrophy , dementia complicate organic disease . Evidence clinically significant , active gastrointestinal , renal , hepatic , endocrine cardiovascular system disease . Evidence second third degree heart block . Patients controlled hypertension ( supine diastolic blood pressure ( BP ) &lt; 95 mmHg ) , right bundle branch block ( complete partial ) pacemaker may include study . Patients previously treat centrally active acetylchlinesterase ( AChE ) inhibitor ( e.g. , physostigmine , tacrine , metrifonate , galantamine , rivastigmine , donepezil ) except medication Aricept doubleblind study E2020E044316 ( NCT00165815 ) . Patients and/or caregivers/study partner unwilling unable fulfill requirement study . Any condition would make patient caregiver/study partner , opinion investigator , unsuitable study . Patients know hypersensitivity AChE inhibitor . Patients noncompliant inclusion/exclusion criterion study medication receive precede Aricept ? doubleblind study E2020E044316 ( NCT00165815 ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>